JP2002519425A5 - - Google Patents

Download PDF

Info

Publication number
JP2002519425A5
JP2002519425A5 JP2000558102A JP2000558102A JP2002519425A5 JP 2002519425 A5 JP2002519425 A5 JP 2002519425A5 JP 2000558102 A JP2000558102 A JP 2000558102A JP 2000558102 A JP2000558102 A JP 2000558102A JP 2002519425 A5 JP2002519425 A5 JP 2002519425A5
Authority
JP
Japan
Prior art keywords
carbons
halide
conr
patient
nhcor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002519425A (ja
Filing date
Publication date
Priority claimed from US09/109,131 external-priority patent/US6013646A/en
Application filed filed Critical
Publication of JP2002519425A publication Critical patent/JP2002519425A/ja
Publication of JP2002519425A5 publication Critical patent/JP2002519425A5/ja
Pending legal-status Critical Current

Links

JP2000558102A 1998-07-02 1999-06-23 神経変性疾患および癌の処置に有用な新規なインドロカルバゾール誘導体 Pending JP2002519425A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/109,131 1998-07-02
US09/109,131 US6013646A (en) 1998-07-02 1998-07-02 Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
PCT/EP1999/004369 WO2000001699A1 (en) 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Publications (2)

Publication Number Publication Date
JP2002519425A JP2002519425A (ja) 2002-07-02
JP2002519425A5 true JP2002519425A5 (https=) 2006-08-10

Family

ID=22325955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558102A Pending JP2002519425A (ja) 1998-07-02 1999-06-23 神経変性疾患および癌の処置に有用な新規なインドロカルバゾール誘導体

Country Status (6)

Country Link
US (2) US6013646A (https=)
EP (1) EP1091962A1 (https=)
JP (1) JP2002519425A (https=)
AU (1) AU754399B2 (https=)
CA (1) CA2336419A1 (https=)
WO (1) WO2000001699A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
WO2001085151A2 (en) * 2000-05-08 2001-11-15 Psoriasis Research Institute Chimeric animal model and treatment of psoriasis
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US20030130252A1 (en) * 2001-12-13 2003-07-10 Pharmacyclics, Inc. Process for affecting neurologic progression
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
CA2477604A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
JP2008539721A (ja) * 2005-05-02 2008-11-20 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク アルツハイマー病の治療のためのホスホイノシチドモジュレーション
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
DE69233330T2 (de) * 1991-08-09 2005-03-10 Massachusetts Institute Of Technology, Cambridge Verwendung eines inhibitors der tau/neurofilament proteinkinase pk40
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE69326388T2 (de) * 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur Herstellung von Staurosporin-Derivaten
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
WO1994004541A2 (en) * 1992-08-12 1994-03-03 The Upjohn Company Protein kinase inhibitors and related compounds combined with taxol
WO1994020106A1 (fr) * 1993-03-03 1994-09-15 Kyowa Hakko Kogyo Co., Ltd. Renforceur de sensibilite pour agent antineoplasique
DE69409641T2 (de) * 1993-05-28 1998-11-26 Cephalon, Inc., West Chester, Pa. Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
ES2236702T3 (es) * 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5648378A (en) * 1995-06-07 1997-07-15 Research Corporation Technologies, Inc. 2-iminochromene derivatives as inhibitors of protein tyrosine kinase
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Similar Documents

Publication Publication Date Title
JP2002519425A5 (https=)
JP2003531118A5 (https=)
JP2001526218A5 (https=)
MY118156A (en) Oral compositions of levosimendan.
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
JP2003521471A5 (https=)
JP2003509349A5 (https=)
JP2004504406A5 (https=)
JP2002508361A5 (https=)
JP2002531505A5 (https=)
JP2002510633A5 (https=)
JP2002520282A5 (https=)
JP2003519228A5 (https=)
JP2003502367A5 (https=)
JP2002537258A5 (https=)
JP2007532607A5 (https=)
JP2004502732A5 (https=)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2002522501A5 (https=)
JP2001520994A5 (https=)
JP2002508373A5 (https=)
JP2002506864A5 (https=)
JP2002520286A5 (https=)
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine